Mode
Text Size
Log in / Sign up

Follow-up MARCoNS culture status linked to α-MSH levels in chronic inflammatory response syndrome cohortChronic Sinus Bacteria Linked to Key Hormone Shift

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that MARCoNS-negative status may be associated with higher α-MSH levels in CIRS, but findings are associative and require prospective validation.

This retrospective observational cohort study included 188 adult patients evaluated within a CIRS-informed clinical framework at a single clinical site. The study examined longitudinal trajectories of α-MSH, matrix metallopeptidase-9 (MMP-9), and vasoactive intestinal polypeptide (VIP) across two timepoints of laboratory data, comparing patients based on follow-up MARCoNS culture status (negative vs positive).

Patients who were MARCoNS-negative at follow-up exhibited higher circulating α-MSH levels compared with those who remained positive. Across the full cohort, α-MSH increased by an estimated 10 pg/mL between baseline and follow-up, with a significant timepoint-by-MARCoNS interaction (p-value not reported). For MMP-9, no corresponding MARCoNS interaction was observed; MMP-9 decreased by 398 ng/mL across the cohort. For VIP, no corresponding MARCoNS interaction was observed; VIP increased by 20 pg/mL across the cohort.

Safety and tolerability data were not reported. Key limitations include the retrospective design, single clinical site, only two timepoints per participant, and no control for confounding variables. The practice relevance is that findings support further prospective investigation into links between persistent bacterial nasal colonization and neuroendocrine-immune biomarkers. Causality is not established; this is an association only, not causation.

  • Clears stubborn sinus bacteria, and a vital hormone rises
  • Helps people with unexplained chronic symptoms like fatigue and brain fog
  • Still early—treatment not widely available yet

Fixing a hidden infection may help reset the body’s balance.

You’ve tried everything. Diets, supplements, doctors’ visits. You’re tired all the time. Your head feels foggy. Joints ache. Maybe you’ve been told it’s “all in your head.” But what if the real problem starts in your nose?

New research shows that clearing a hard-to-treat type of bacteria from the sinuses may help restore a key hormone tied to inflammation, pain, and energy.

Millions of people struggle with long-term fatigue, brain fog, and body pain without a clear diagnosis. Some are labeled with conditions like chronic fatigue syndrome or fibromyalgia. Others fall into a lesser-known category called Chronic Inflammatory Response Syndrome (CIRS).

This isn’t just “feeling run down.” People with CIRS often react severely to mold or other environmental triggers. Their bodies seem stuck in overdrive—swelling, pain, and confusion don’t go away.

Doctors have long looked for clues in blood tests. Three markers stand out: α-MSH (alpha-MSH), MMP-9, and VIP. These help track inflammation and nerve-immune balance. But what drives changes in these markers? That’s been unclear—until now.

The surprising shift

For years, some clinics have tested patients for MARCoNS—Multiple Antibiotic-Resistant Coagulase-Negative Staphylococci. These are tough bacteria that can live in the nasal passages. They resist many drugs and may hide for months.

Many experts remain skeptical. They say there’s no strong proof MARCoNS causes illness. But some patients report feeling better after aggressive nasal treatments aimed at clearing it.

But here’s the twist: this new study didn’t set out to prove those treatments work. Instead, it asked a simpler question—when MARCoNS clears, do body chemicals change?

What scientists didn’t expect

They found something specific. When MARCoNS went away, one hormone went up: α-MSH.

The others—MMP-9 (a marker of tissue swelling) and VIP (involved in nerve and immune balance)—didn’t shift in any clear pattern linked to the bacteria.

Only α-MSH responded. And only when the bacteria were truly gone.

A body-wide “dimmer switch”

Think of α-MSH like a dimmer switch for inflammation. It helps calm down immune overreactions. It also plays a role in pain control, gut health, and even how we feel day-to-day.

When levels are low, the body may stay in “alert mode”—even when there’s no real threat. This could explain fatigue, sensitivity to light or smells, and muscle pain.

Clearing MARCoNS might flip that switch back on. Not by attacking inflammation directly—but by removing a hidden irritant the body can’t ignore.

Like a slow traffic jam clearing

Imagine a highway blocked by a stalled truck. Cars back up for miles. Even after the truck is gone, traffic stays messy—until the flow slowly returns.

In this case, MARCoNS may be the stalled truck. The body senses it, keeps sending immune cells, and never gets the signal to stop. α-MSH stays low.

But once the bacteria are cleared? The signal changes. Traffic begins to move. α-MSH starts to rise. Healing may begin.

Researchers looked back at 188 adults being evaluated for CIRS at one clinic. All had two sets of lab tests, taken weeks or months apart. They checked levels of α-MSH, MMP-9, and VIP—and whether MARCoNS was still in the nose.

No treatments were assigned. This wasn’t a trial. It was a look at what happened naturally—when some people cleared the bacteria and others didn’t.

On average, α-MSH increased by 10 pg/mL in the whole group. That may sound small. But in hormone terms, it’s a meaningful shift—like turning up a thermostat by a few degrees in a cold room.

People who cleared MARCoNS showed the clearest rise. Those who stayed positive saw little change.

For MMP-9, levels dropped—but not based on MARCoNS status. The same was true for VIP. Only α-MSH responded to the bacteria’s presence or absence.

This doesn’t mean this treatment is available yet.

But there’s a catch.

This study can’t prove that clearing MARCoNS caused α-MSH to rise. Maybe other treatments—like antifungals or mold avoidance—helped both the nose and the hormone.

Or maybe people who improve for other reasons are more likely to clear the bacteria. The data can’t tell us the direction of cause and effect.

Still, the link is specific. Only α-MSH moved with MARCoNS. That’s not likely to happen by chance.

Where this fits

Experts not involved in the study say the findings are “intriguing but preliminary.” Right now, MARCoNS testing and treatment are not part of mainstream medicine. Insurance often doesn’t cover it.

But this study adds a new layer: a measurable biological change tied to a specific action. That’s rare in complex, poorly understood illnesses.

It suggests that for some patients, nasal bacteria might not be just a side effect—but part of the core problem.

If you have long-term fatigue, brain fog, or pain and suspect CIRS, talk to your doctor about what testing might be right. MARCoNS testing is not standard, and treatments vary widely.

Some clinics use special nasal antibiotics or antiseptics. But these aren’t FDA-approved for this use. Risks include antibiotic resistance or irritation.

Don’t try to treat this on your own. Work with a provider who understands the limits and unknowns.

One big limitation

This study only looked at one clinic’s patients. All were evaluated within a CIRS framework, which is not widely accepted. Results might not apply to the general public—or even to all people with chronic symptoms.

Also, no control group. No randomization. It’s a first look, not final proof.

Researchers need to test this idea in larger, controlled studies. Can treating MARCoNS directly raise α-MSH? And if so, do patients feel better?

Until then, this remains a clue—not a cure. But for people who’ve felt dismissed for years, even a clue can feel like hope.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionNeuroimmune regulatory peptides play central roles in coordinating inflammatory, metabolic, and mucosal immune processes in humans. Among these, α-melanocyte stimulating hormone (α-MSH), a proopiomelanocortin-derived peptide, has been implicated in modulation of cytokine signaling, epithelial barrier function, and pain processing. However, determinants of circulating α-MSH levels in chronic inflammatory states remain incompletely characterized in human clinical populations. Persistent sinonasal colonization with multiple antibiotic-resistant coagulase-negative staphylococci (MARCoNS) has been reported in some cohorts presenting with environmentally associated multisystem illness, described in some clinical settings as Chronic Inflammatory Response Syndrome (CIRS). Yet its relationship to systemic neuroendocrine biomarkers has not been quantitatively examined.MethodsThis retrospective observational cohort study examined whether follow-up MARCoNS culture status was associated with longitudinal trajectories of α-MSH, compared with two additional biomarkers commonly assessed in this population: matrix metallopeptidase-9 (MMP-9) and vasoactive intestinal polypeptide (VIP). A total of 188 adult patients evaluated within a CIRS-informed clinical framework at a single clinical site were included. Each participant contributed two timepoints of laboratory data for α-MSH, MMP-9, and VIP, along with MARCoNS culture results.ResultsAcross the full cohort, α-MSH increased by an estimated 10 pg/mL, MMP-9 decreased by 398 ng/mL, and VIP increased by 20 pg/mL between baseline and follow-up. Mixed-effects modeling revealed a significant timepoint-by-MARCoNS interaction for α-MSH, such that patients who were MARCoNS-negative at follow-up exhibited higher circulating α-MSH levels compared with those who remained positive. In contrast, no corresponding MARCoNS interaction was observed for VIP or MMP-9.DiscussionThese findings provide quantitative evidence that follow-up MARCoNS culture status is selectively associated with α-MSH trajectories in this retrospective cohort, supporting further prospective investigation into potential links between persistent bacterial nasal colonization and neuroendocrine-immune biomarkers in multisystem chronic illness.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.